Merus N.V. | Mutual Funds
Mutual Funds that own Merus N.V.
Tekla Healthcare Investors
336,567
1.49%
0
0.65%
12/31/2017
T Rowe Price Health Sciences Fund
278,912
1.23%
-5,692
0.05%
06/30/2018
80,786
0.36%
-18,175
0.39%
05/31/2018
VALIC Company I - Health Sciences Fund
19,000
0.08%
-700
0.05%
02/28/2018
T Rowe Price Health Sciences Portfolio
17,200
0.08%
0
0.05%
06/30/2018
TD Health Sciences Fund
15,000
0.07%
-2,100
0.05%
12/31/2017
Fidelity Nasdaq Composite Index
12,614
0.06%
0
0%
07/31/2018
John Hancock II - Health Sciences Fund
7,182
0.03%
-800
0.04%
05/31/2018
APO Medical Opportunities Institutionell
7,000
0.03%
0
0.08%
06/29/2018
John Hancock VIT - Health Sciences Trust
6,900
0.03%
-300
0.04%
03/31/2018
| Address |
Yalelaan 62
Utrecht Utrecht 3584 CH
Netherlands
|
|
Employees
|
- |
| Website |
http://www.merus.nl |
| Updated |
07/08/2019 |
| Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands. |
